Not for human consumption

GLP1 – Tirz | Dual GIP/GLP-1 Receptor Agonist Research Peptide

Name: GLP-1 Tirz (Tirzepatide) | Research Grade
Brand: LiveWell Peptides
SKU: LWP-TIRZ-VAR
Availability: InStock

Price range: $ 99.00 through $ 250.00 - or subscribe

GLP1 – Tirz is a 39-amino-acid dual receptor agonist peptide that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, studied for its role in dual incretin pathway signaling and metabolic regulation in research models. Supplied as a lyophilized vial for in-vitro laboratory research use only.

Research-grade specs

Sequence length: 39 amino acids
Class: Dual GIP / GLP-1 agonist
Half-life: ~5 days

Studied applications

Comparative GLP-1 vs dual-agonist research
Glucose and lipid metabolism studies
Body-composition research (SURMOUNT trial framework)
Receptor-binding affinity comparison studies

Quality & trust

≥99% HPLC purity, third-party tested
Mass spectrometry identity confirmation
LAL endotoxin testing on every batch
Batch-specific Certificate of Analysis included
USA same-day shipping (orders before 2pm CT M-F)

Related research: Semaglutide · Retatrutide

Research literature

Tirzepatide has been the subject of 1,927 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference:

Johansson E et al. (2026). Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. J Med Econ. PMID: 42012820
Kanumilli N et al. (2026). Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. J Med Econ. PMID: 41771166
Soliman A et al. (2026). Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. J Diabetes Metab Disord. PMID: 41883513
Alexander L et al. (2026). Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach. Obes Pillars. PMID: 41859682
Mondoh A et al. (2026). Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. Obes Pillars. PMID: 41815755

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Size

Clear

Get Started:

One-time purchase
Subscribe and save up to 10%

Quantity	Price	Discount
3-5	$ 95.04	4%
6-8	$ 91.08	8%
10-15	$ 88.11	11%
16+	$ 99.00	$ 0.00

Add $ 200.00 to cart and get free shipping!

Description

GLP-1 Tirz is a dual GLP-1/GIP receptor agonist peptide that has become a subject of growing scientific interest in metabolic and endocrinology research. This lyophilized peptide is designed strictly for laboratory and in-vitro investigations, allowing researchers to explore pathways associated with glucose regulation, energy balance, and cardiovascular health.

GLP-1 Tirz (5mg): The 5mg vial provides a precise research format suitable for controlled in-vitro testing. It is frequently investigated in studies focusing on advanced metabolic regulation, cellular response to glucose signaling, and GLP-1 and GIP receptor interaction dynamics in controlled assay conditions. Reference Link: Click Here

GLP-1 Tirz (20mg): The higher-dose 20mg vial offers a concentrated research option, ideal for projects that require intensified examination of dual receptor signaling mechanisms and metabolic pathway interactions. It enables researchers to expand upon foundational findings and evaluate dose-dependent variations in laboratory models. Reference Link:

Reference Link: Click Here